Alzheimer's disease
We have entered a new era in Alzheimer’s disease therapy following the FDA approval of amyloid-β-targeting monoclonal antibodies, the first disease-modifying therapies to enter clinical use. Here, Nature and Nature Reviews Neurology celebrate the milestones in the Alzheimer’s disease research field that have moved us closer to early and effective intervention.
This Milestone will launch in full in Summer 2024. A collection of related articles from across the Nature Portfolio is available to access now.
This Milestone is editorially independent, produced with financial support from a third party. About this content.
Nature Portfolio is pleased to acknowledge financial support from Eisai in producing this Milestone. The sponsor retains sole responsibility for the following message.
Eisai is your partner in a new era of Alzheimer's disease (AD). A new age for AD stands before us, with unprecedented possibilities for patients, care partners, and health care professionals. Eisai's four decades of AD research helped pave the way for scientific breakthroughs and advances that are shaping the future of neurology. Paired with our long-term vision and commitment to our human health care (hhc) mission, we use deep human biology and genetic evidence with the goal of providing the right intervention, for the right person, at the right time. Eisai’s rich neurology pipeline builds upon our pioneering history. From the research and development of a symptomatic breakthrough treatment in the 1980s, to our continued development of anti-amyloid-beta and anti-tau antibodies, we stand at the forefront of dementia research.